RGEN

Repligen Corporation

Price

$176.36

return (12m)

42.80%

p/e

225.28

p/bv

4.43

DIVIDEND YIELD

0.00%

RGEN price

Repligen

If you had invested

exposure

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Return on Investment RGEN

1 month

3 months

1 year

2 years

5 years

10 years

return

1 month

31.06%

3 months

55.56%

1 year

42.80%

2 years

14.65%

5 years

-32.86%

10 years

0.00%

Asset Comparator

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Fundamentals RGEN

Valuation

P/E

225.28

Sector -4.38

Industry -4.38

P/BV

4.43

Sector 2.02

Industry 2.02

P/Revenue (PSR)

11.92

Sector -4.40

Industry -4.40

EV/EBITDA

208.74

Sector -263.09

Industry -263.09

EV/EBIT

459.07

Sector -702.90

Industry -702.90

P/EBITDA

54.53

Sector -4.39

Industry -4.39

P/EBIT

125.93

Sector -4.73

Industry -4.73

P/Total Assets

3.17

Sector 1.49

Industry 1.49

P/Net Current Assets

25.82

Sector -11.70

Industry -11.70

P/Working Capital

8.76

Sector -3.19

Industry -3.19

EPS

0.74

Sector -2.14

Industry -2.14

BVPS

37.71

Sector 1.85

Industry 1.85

Efficiency

Gross Margin

53.84%

Sector 36.74%

Industry 36.74%

EBITDA Margin

21.35%

Sector -16,244.81%

Industry -16,244.81%

EBIT Margin

9.71%

Sector -4,202,541.34%

Industry -4,202,541.34%

Operating Margin

8.32%

Sector -38.22%

Industry -38.22%

Net Profit Margins

5.29%

Sector -39.69%

Industry -39.69%

Asset Turnover

0.07

Sector 0.03

Industry 0.03

Profitability

ROE

1.97%

Sector -65.14%

Industry -65.14%

ROA

1.41%

Sector -65.53%

Industry -65.53%

ROIC

1.29%

Sector -2,103.35%

Industry -2,103.35%

Dividends

Dividend yield

0.00%

Sector -

Industry -

Payout

0.00%

Sector -

Industry -

Debt

Current Ratio

9.05

Sector 2.90

Industry 2.90

Net Debt / EBITDA

-5.95

Sector -6.07

Industry -6.07

Net Debt / EBIT

-13.09

Sector -8.26

Industry -8.26

Net Debt / Equity

-0.12

Sector -1.07

Industry -1.07

Gross Debt / Equity

0.26

Sector -0.05

Industry -0.05

Equity/Assets

0.72

Sector 0.41

Industry 0.41

Liabilities/Assets

0.28

Sector 0.39

Industry 0.39

Growth

5Y Revenue CAGR

3.20%

Sector -

Industry -

5Y Earnings CAGR

-20.19%

Sector -

Industry -

FAIR VALUE OF Repligen ACCORDING TO BENJAMIN GRAHAM

Graham's Fair Value

The Fair Value formula was created by Benjamin Graham to identify stocks with appreciation potential or that are being traded for less than they are worth. Graham was one of the greatest investors in history and Warren Buffett’s mentor.

Current price

$176.36

Fair Value

$25.06

Upside Return potential.

-85.79%

See Graham's ranking

Because it considers equity value in its calculation, this formula may not work well for technology companies.

This is not a buy/sell recommendation; the fair value calculation takes into account only the formula created by Benjamin Graham, published in the book The Intelligent Investor.

Fundamentals RGEN

DRAG THE FRAME TO SEE MORE DATA

Assets	Price (US$)	Return 12m	DY	P/E	P/BV	ROE	Net Profit Margins
RGEN Repligen Corporation	$176.36	42.13%	0.00%	225.28	4.43	1.97%	5.29%
JNJ Johnson & Johnson	$273.41	58.46%	2.02%	29.66	7.34	24.76%	21.48%
PFE Pfizer Inc.	$28.24	21.45%	6.54%	34.62	1.75	5.07%	6.80%
ABBV AbbVie Inc.	$265.97	33.11%	2.73%	70.02	-74.53	-106.44%	9.81%
NVO Novo Nordisk A/S	$46.48	-9.14%	4.09%	11.13	5.91	53.11%	35.32%
MRK Merck & Co. Inc.	$152.20	87.95%	2.45%	106.68	8.06	7.56%	4.77%
AZN AstraZeneca PLC	$164.95	4.92%	2.07%	22.98	4.77	20.74%	17.02%
BMY Bristol-Myers Squibb Company	$67.61	46.95%	3.93%	14.06	5.85	41.59%	18.87%
ZTS Zoetis Inc.	$76.68	-48.52%	2.77%	11.89	9.88	83.10%	27.49%
REGN Regeneron Pharmaceuticals Inc.	$840.84	43.05%	0.45%	19.09	2.61	13.65%	27.86%
AMGN Amgen Inc.	$442.36	55.11%	2.39%	25.30	18.93	74.80%	22.95%
HALO Halozyme Therapeutics Inc.	$107.62	56.06%	0.00%	27.82	80.17	288.14%	24.86%
MCK McKesson Corporation	$853.71	27.85%	0.38%	22.42	-79.15	-352.96%	1.12%
VRTX Vertex Pharmaceuticals Incorporated	$552.06	41.60%	0.00%	29.26	6.36	21.76%	35.00%
CAH Cardinal Health Inc.	$234.85	58.85%	0.88%	31.61	-19.89	-62.92%	0.67%
HRMY Harmony Biosciences Holdings Inc.	$39.93	9.67%	0.00%	12.18	2.21	18.14%	18.89%
BIIB Biogen Inc.	$221.56	63.02%	0.00%	37.04	1.64	4.43%	8.32%

Stock vs Indice Comparison Tool

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

RGEN Historical Dividends

current DY: 0.00%

5-year average DY: 0.00%

no dividend paid in the period.

ABOUT Repligen

Repligen Corporation

Average Investor10 user rating

4.0 (0 people)

United States

45 years

Founded: 1981

1986

Time since IPO - 40 years

761

Employees

Repligen Corporation (United States) is listed on the Nasdaq and has a market capitalization of $9.36 billion, with shareholders equity totaling $2.11 billion.

The company employs approximately 761 people and operates in the Health Care sector, within the Biotechnology industry.

Over the past 12 months, Repligen Corporation reported $785.10 million in revenue, generating net income of $41.54 million.

Key financial metrics include a P/E ratio of 225.28, a price-to-book (P/B) ratio of 4.43, and a trailing twelve-month dividend yield of 0.00%.

The company trades under the ticker RGEN.

Market cap

$9.36 billion

Net worth

$2.11 billion

$2,112,030,000.00

Assets

$2.95 billion

$2,950,180,000.00

Total Shares Outstanding

56.00 million

56,000,000

Average Daily Trading Volume

$1.14 million

$1,143,682.00

Sector

Health Care

Industry

Biotechnology

RGEN

RGEN revenue and profits

Financial Results RGEN

DRAG THE FRAME TO SEE MORE DATA

RGEN cash flow

DRAG THE FRAME TO SEE MORE DATA

Discover more assets

BFRA - Biofrontera

$- -0,00% (12M)

P/E

0.00

0.00%

ROE

-893.55%

P/BV

0.00

MCK - McKesson

$853.71 22,07% (12M)

P/E

22.42

0.38%

ROE

-352.96%

P/BV

-79.15

CAH - Cardinal Health

$234.85 55,51% (12M)

P/E

31.61

0.88%

ROE

-62.92%

P/BV

-19.89

JNJ - Johnson & Johnson

$273.41 57,54% (12M)

P/E

29.66

2.02%

ROE

24.76%

P/BV

7.34

ABBV - AbbVie

$265.97 31,23% (12M)

P/E

70.02

2.73%

ROE

-106.44%

P/BV

-74.53

MRK - Merck & Co.

$152.20 86,97% (12M)

P/E

106.68

2.45%

ROE

7.56%

P/BV

8.06

AZN - AstraZeneca

$164.95 5,00% (12M)

P/E

22.98

2.07%

ROE

20.74%

P/BV

4.77

PFE - Pfizer

$28.24 21,16% (12M)

P/E

34.62

6.54%

ROE

5.07%

P/BV

1.75

BFRA - Biofrontera

$- -0,00% (12 M)

P/L

0.00

0.00%

ROE

-893.55%

P/VP

0.00

MCK - McKesson

$853.71 22,07% (12 M)

P/L

22.42

0.38%

ROE

-352.96%

P/VP

-79.15

CAH - Cardinal Health

$234.85 55,51% (12 M)

P/L

31.61

0.88%

ROE

-62.92%

P/VP

-19.89

JNJ - Johnson & Johnson

$273.41 57,54% (12 M)

P/L

29.66

2.02%

ROE

24.76%

P/VP

7.34

ABBV - AbbVie

$265.97 31,23% (12 M)

P/L

70.02

2.73%

ROE

-106.44%

P/VP

-74.53

MRK - Merck & Co.

$152.20 86,97% (12 M)

P/L

106.68

2.45%

ROE

7.56%

P/VP

8.06

AZN - AstraZeneca

$164.95 5,00% (12 M)

P/L

22.98

2.07%

ROE

20.74%

P/VP

4.77

PFE - Pfizer

$28.24 21,16% (12 M)

P/L

34.62

6.54%

ROE

5.07%

P/VP

1.75

Frequently Asked Questions

What is the price of Repligen (RGEN) today?

A cotação de Repligen (RGEN) hoje está em US$ 176.36, com uma variação de 42.8% em relação ao último ano. A cotação de Repligen (RGEN) iniciou o ano negociando na casa dos US$ 163.86 e hoje está em US$ 176.36. Acompanhe o gráfico de cotação em tempo real, a cotação histórica de Repligen (RGEN) e dados de ações do Ibovespa e mercados internacionais.

Quando Repligen (RGEN) paga dividendos?

Repligen (RGEN) não distribuiu dividendos no último ano.

Is Repligen (RGEN) a good investment?

Atualmente, Repligen (RGEN) está cotada a US$ 176.36, com um P/L de 225.28, representando um desvio de 8,684% em relação ao seu P/L médio histórico. No último ano, a ação apresentou uma variação de 42.8 em sua cotação e distribuiu US$ 0.00 em dividendos, resultando em um Dividend Yield de 0.00%. O retorno total do acionista foi de 42.80%.

Investors should keep in mind that past performance does not guarantee future results. This information is provided for educational purposes only and should not be considered investment advice.

How can I buy Repligen (RGEN) stock?

Investir em ações de Repligen (RGEN) pode ser feito de duas formas: comprando a stock uma empresa estrangeira e é atrelado ao dólar.

How much would 100 shares of Repligen (RGEN) yield today?

A rentabilidade de Repligen (RGEN) foi de 31.06% no último mês, 42.80% no último ano e -32.86% nos últimos 5 anos (já considerando valorização e dividendos).

Nos últimos 12 meses, a empresa pagou um total de US$ 0.00 em dividendos, um Dividend Yield de 0.00%.

Se você quisesse comprar 100 ações de Repligen (RGEN) hoje, o investimento total seria de US$ 17,636.00, com base na cotação atual de US$ 176.36.

Based on historical performance, the investment would have grown to approximately:

Em 1 ano: US$ 25,184.21
Em 5 anos: US$ 11,840.81
Em 10 anos: US$ 17,636.00

Past performance does not guarantee future results. This content is for informational purposes only and should not be considered investment advice.

RGEN

Repligen Corporation

Price

return (12m)

p/e

p/bv

DIVIDEND YIELD

Return on Investment RGEN

Valuation

Efficiency

Profitability

Dividends

Debt

Growth

Graham's Fair Value

COMPARING RGEN WITH OTHER STOCK

current DY: 0.00%

5-year average DY: 0.00%

ABOUT Repligen

Repligen Corporation

United States

45 years

1986

761

PROFIT X PRICE RGEN

Financial Results RGEN

RGEN cash flow

Asset, Revenue and Profit Growth - RGEN

RGEN balance sheet

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

Frequently Asked Questions